Arno Therapeutics Inc.
Description Arno Therapeutics, Inc., a development stage biopharmaceutical company, focuses on developing products for the treatment of cancer. Its product development pipeline includes Onapristone, an anti-progestin hormone blocker, which is in pre-clinical toxicology studies for the treatment of breast and endometrial cancer; AR-42, an orally available spectrum inhibitor of histone and non-histone deacetylation proteins that is in Phase I/IIa clinical study for the treatment of hematological malignancies and solid tumors; and AR-12, an anti-cancer agent, which is in Phase I clinical study for the treatment of solid tumors and hematological malignancies. The company is based in Flemington, New Jersey. To view the detailed information, you need to SUBSCRIBE with us. |
 |